Business Wire

Carbon Trade eXchange (CTX) Partners With Victoria Falls Carbon Registry & Exchange in Zimbabwe: ‘Making Lemonade out of Lemons’

13.7.2023 20:49:00 EEST | Business Wire | Press release

Share

History was made in Victoria Falls Zimbabwe, on July 7th, 2023, the final day of the inaugural Africa Voluntary Carbon Credits Forum (AVCCM). Agreements were signed to initiate and install a Regional (Pan African) Carbon Registry owned and operated in Zimbabwe plus a locally operated, owned, and branded version of the worlds first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713321840/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Contracts Signed in Victoria Falls Zimbabwe (Photo: Business Wire)

The Victoria Falls Carbon Registry (VFCR) will support the migration of Zimbabwe and other African nations projects and Carbon Credits back to Africa to be re-issued under their control. African Nations wishing to participate will be offered a National Sub-license and Registry Administration role within the VFCR, to support, lodge, monitor and manage projects and credit issuance in their nation. This low-cost solution negates the need for separate National Registries. Project types, methodologies and registry fees will be at the discretion of the VFCR, and they expect support from existing carbon credit standards internationally. The Registry will be operational in August 2023 and will start accepting projects, new or migrating, as soon as staff are trained to do so. Global Environmental Markets Group (GEM) will deliver the technology with training in August.

The Victoria Falls Carbon Exchange (VFCX) will have immediate access via CTX to hundreds of projects worldwide for buyers globally, millions of credits listed across worldwide for T+0 clearance and settlement. Plus new credits issued by VFCR Registry listed on the VFCX /CTX globally) instantly at the price the seller determines from that new registry. VFCX registry account holders can list via VFCX at no costs to list. A 5% fee on Sale of credits, no transfer or Retirement fees.

The AVCCM event attracted a large global audience across the carbon market, plus Government, banking, and project developers, supporting Zimbabwean Government’s decision to bring the carbon credits ‘home’ under the UNFCCC Paris Agreement.

“This is the future Africa said it wanted from the Paris agreement in 2015,” according to Wayne Sharpe, CEO & Founder, Global Environmental Markets Group. This follows on from COP27 where GEM and CTX did multiple presentations to various African nations. After speaking at the AVCCM event, Wayne added, “We saw the passion and commitments to Carbon Credits in Zimbabwe and Africa. This is why we built this technology, to deliver financial and ecological benefits to nations on the ground!

Kwanele Hlabangana, Chairman and Co-Founder of AVCCM said, “Partnering with experienced world class Carbon Market technology leaders like GEM & CTX is exciting. Responses from projects, communities and governments is outstanding. It's a great opportunity to accelerate Africa into the Global Climate to save our planet.” Ground up approach plus community engagement combined with GEM’s proven world class Registry and Exchange technology ticks the boxes for a trusted, credible, transparent, and vibrant African marketplace

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CTX/GEM:
Wayne Sharpe,
CEO and Founder
info@ctxglobal.com
+44 7502 229523,
www.ctxglobal.com
www.gemglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye